Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay.
BACKGROUND
One third of patients with chronic heart failure have electrocardiographic evidence of a major intraventricular conduction delay, which may worsen left ventricular systolic dysfunction through asynchronous ventricular contraction. Uncontrolled studies suggest that multisite biventricular pacing improves hemodynamics and well-being by reducing ventricular asynchrony. We assessed the clinical efficacy and safety of this new therapy.


METHODS
Sixty-seven patients with severe heart failure (New York Heart Association class III) due to chronic left ventricular systolic dysfunction, with normal sinus rhythm and a duration of the QRS interval of more than 150 msec, received transvenous atriobiventricular pacemakers (with leads in one atrium and each ventricle). This single-blind, randomized, controlled crossover study compared the responses of the patients during two periods: a three-month period of inactive pacing (ventricular inhibited pacing at a basic rate of 40 bpm) and a three-month period of active (atriobiventricular) pacing. The primary end point was the distance walked in six minutes; the secondary end points were the quality of life as measured by questionnaire, peak oxygen consumption, hospitalizations related to heart failure, the patients' treatment preference (active vs. inactive pacing), and the mortality rate.


RESULTS
Nine patients were withdrawn from the study before randomization, and 10 failed to complete both study periods. Thus, 48 patients completed both phases of the study. The mean distance walked in six minutes was 22 percent greater with active pacing (399+/-100 m vs. 326+/-134 m, P<0.001), the quality-of-life score improved by 32 percent (P<0.001), peak oxygen uptake increased by 8 percent (P<0.03), hospitalizations were decreased by two thirds (P<0.05), and active pacing was preferred by 85 percent of the patients (P<0.001).


CONCLUSIONS
Although it is technically complex, atriobiventricular pacing significantly improves exercise tolerance and quality of life in patients with chronic heart failure and intraventricular conduction delay.
InParys, Saint-Cloud, France.
S
S
Cazeau
C
C
Leclercq
T
T
Lavergne
S
S
Walker
C
C
Varma
C
C
Linde
S
S
Garrigue
L
L
Kappenberger
G A
GA
Haywood
M
M
Santini
C
C
Bailleul
J C
JC
Daubert
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000628:therapy*; D002304:Cardiac Pacing, Artificial / Q000379:methods*; D002908:Chronic Disease; D003131:Combined Modality Therapy; D018592:Cross-Over Studies; D004232:Diuretics / Q000627:therapeutic use; D017079:Exercise Tolerance; D006333:Heart Failure / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D008875:Middle Aged; D010138:Pacemaker, Artificial; D011788:Quality of Life; D016037:Single-Blind Method; D018487:Ventricular Dysfunction, Left / Q000150:complications
D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics